Immunotherapy combo before kidney surgery shows promise in small trial
NCT ID NCT04028245
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested two immunotherapy drugs (spartalizumab and canakinumab) given before surgery to 17 people with localized clear cell kidney cancer. The main goal was to see if this approach was safe and did not delay surgery. The study also looked at how the drugs affected the immune system and tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Irving Medical Center
New York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personalized vaccine trains immune system to attack kidney cancer blood vessels
- New kidney cancer drug shows promise in early trial
- New hope for advanced kidney cancer: belzutifan takes on everolimus in major trial
- New hope for advanced kidney cancer: Triple-Drug combo shows promise
- New drug cocktail aims to fight advanced cancers
- New hope for advanced kidney cancer: experimental combo therapies under study